** Vaccine maker Moderna's MRNA.O shares down 4.3% at $33.71
** Brokerage Berenberg cuts PT to $30 from $33, maintains rating to "hold"
** The new PT represents 14.7% downside to stock's last close on Wednesday
** Berenberg sees multiple headwinds for MRNA which include a poor commercial outlook for its respiratory vaccines, and an unsupportive U.S. political environment
** Sanofi's SASY.PA entry into the COVID-19 market with the Novavax NVAX.O vaccine will increase pricing pressure and reduce MRNA's market share, brokerage says
** "Moderna will not meet its guidance to break even by 2028 on our forecasts," brokerage adds
** Two brokerages rate stock "buy" or higher, seven "hold" or equivalent, and one "underperform"; their median PT is $54.51, according to data compiled by LSEG
** MRNA has fallen 63.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.